Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
Rui Li(Max Planck Institute of Immunobiology and Epigenetics), Yusei Miyazaki(National Hospital Organization Hokkaido Medical Center), Jennifer L. Gommerman(University of Toronto), Simon Fillatreau(Hôpital Necker-Enfants Malades), Hanane Touil(Institute of Neuroimmunology of the Slovak Academy of Sciences), Faisal Althekair(Montreal Neurological Institute and Hospital), Ping Shen(Humboldt-Universität zu Berlin), Ellen Hilgenberg, Alexandre Prat(Université de Montréal), Amit Bar‐Or(University of Pennsylvania), Ayman Rezk(Montreal Neurological Institute and Hospital), Laure Michel(Centre Hospitalier Universitaire de Rennes), Craig S. Moore(Memorial University of Newfoundland), Sathy Rajasekharan(Montreal Neurological Institute and Hospital)
Cited by 453
Related Papers
The Blood–Brain Barrier
|Cold Spring Harbor Perspectives in Biology|2015|3.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
B cells regulate autoimmunity by provision of IL-10
|Nature Immunology|2002|1.6k